Ready for another round of re-rating even in a volatile market? 5 Indian Pharma stocks with upside potenti
In the last two years, every sector has come into focus at one point of time or the other. Some came into limelight due to the fact of real positive changes in the fundamental operating matrix of that sector. While others came into focus just because of too much liquidity chasing Indian paper. In the case of the Pharma sector, after years of consolidation, valuation readjustment and regulatory learning which altogether led to positive change in the fundamentals, the stocks made a comeback. It is almost a period of six to eight years that the industry is back on the list where there are more positive developments than negative. These changes have come after the management of a large number of Pharma companies learnt the lesson hard way. The lessons that expansion based on PPT presentations on market growth are probably not the best way to run business, rather ensuring compliance to regulatory requirements is more important. So sectors like Pharma which have seen a very long phase of business remodelling and valuation readjustment need to be brought back on the watch list. Key Points
Economic TimesOmega bull run: Mid, smallcaps to outperform for 5-10 years; largecaps also do well: Vikas Khemani
Vikas Khemani, Founder of Carnelian Asset Advisors, discusses the mantra of faster, stronger, cheaper for portfolio growth. He believes that midcaps and smallcaps will outperform in the next 5-10 years, while largecaps will also do well. He highlights the growth potential in the Pharma sector and opportunities in the API space, ER&D companies, manufacturing, and capital market-focused AMCs. Key Points
Economic TimesAditya Arora on where money can be made in Pharma space
Aditya Arora of Adlytick maintains a cautious view on the market due to the lack of broad-based rally. Smallcaps are correcting while safe havens like gold and Pharma are performing well. Money can be made on the long side of the Pharma space and the short side of high beta counters. Key Points
Economic TimesSAIL is the new GAIL? Sanjiv Bhasin’s 3 dark horse picks in metal pack
Sanjiv Bhasin of IIFL Securities remains bullish on metals, oil marketing companies, AU Bank, Bank Nifty, and Pharma stocks like Aurobindo Pharma, Suven Pharma, Lupin, and Biocon. He advises staying invested in the real estate sector and buying Indiabulls Real Estate due to its merger with Embassy. Also, the best thing to buy is the SBI Pharma Fund or the Nippon Pharma Fund. Mirae, these three have a good portfolio, they have a very active fund management team. Key Points
Economic TimesGovt departments split as trade talks with European Pharma firms hit last lap, patent key issue
Last month, at least two meetings were held between representatives of India & European Free Trade Association. The FTA with the 4-nation bloc is likely to be finalised this month. Key Points
ThePrint
Business and valuation tailwinds to help in outperformance? 5 Indian Pharma stocks with upside potential o
Just before the whole market was consumed by the PSU rally, one sector that came into the limelight after many years of underperformance was the Indian Pharma companies, yes they are very different in every sense from MNC pharma. During the PSU rally, these Pharma stocks have been consolidating, however, in the last few days, some of them have once again started reacting to positive developments in the individual company indicating that there is money on the sideline that is ready to come into these stocks. Sectors like Pharma which have seen a very long phase of business remodelling and valuation readjustment need to be brought back on the watch list. It might be too early to call, but if a re-rating gets momentum once again then they might be better candidates for volatile markets. Key Points
Economic TimesCan there be value buying in HDFC Bank? Should one go for upstream oil cos? Nitin Raheja answers
Nitin Raheja discusses challenges faced by OMCs, the pressure on HDFC Bank, re-rating of defence stocks, performance of upstream oil companies, and the positive outlook for the Pharma sector. Coming to HDFC Bank, he says we are getting to that stage where there is clearly value sitting there. It is only a question of when you start seeing the flow ease off and I think that will happen sooner than later. Key Points
Economic TimesPramod Amthe is selective in midcaps; betting on 4 Pharma stocks
The better way to play Pharma is Sun Pharma and Aurobindo which we like. The other trend is domestic outlook for the growth for pharma. The proxy there is Torrent and Ajanta.Railways have new avenues of growth and strong momentum. Medium-term targets and government support improve growth prospects. Larger railway stocks like Concor, Kalpataru, and KEC are attractive due to their involvement in electrification lines. Having said that, some of the mid and smallcaps have run up much sharper. Key Points
Economic TimesPharma largecaps doing well, 3 stocks to bet on: Rahul Shah
Rahul Shah, VP-Equity Advisory, MOFSL, says most of the IT names have gone up quite sharply post their Q3 numbers. Now it is the turn of pharma. Shah expects largecap Pharma stocks like Sun Pharma, Cipla, and Dr Reddy's to maintain their good performance. The market is undergoing sector rotation, with IT stocks performing well and now Pharma stocks gaining momentum. Key Points
Economic TimesGovt departments split as trade talks with European Pharma firms hit last lap, patent key issue
Last month, at least two meetings were held between representatives of India & European Free Trade Association. The FTA with the 4-nation bloc is likely to be finalised this month. Key Points
ThePrint
Aditya Arora is bullish on Nifty Pharma, sees last leg of rally in high beta counters post Budget
Aditya Arora is tracking Nifty Pharma and mentions good moves in Cipla, Dr Lal Path Lab, and Metropolis. The chart structure of many Pharma counters has improved. On the flip side, many financials or cyclical stocks appear to be topping out. Indiabulls Housing Finance is breaking out with volume support. Aditya Arora recommends buying it at Rs 215 with a stop loss at Rs 190 and a target of Rs 230 to 250. Key Points
Economic TimesMankind Pharma Block Deal: Chrys Capital divests stake worth ₹3,200 crore, Beige sells 1.44 crore shares
Kotak Mutual Funds acquired 2 million shares in the pharmaceutical company at a price of ₹1,832.30 per share. Key Points
mintUS regulators inspect Dr Reddy's, other Indian Pharma majors
The U.S. Food and Drug Administration is inspecting Dr Reddy's (REDY.NS) research and development centre in the southern Indian city of Hyderabad, the Pharma company said on Tuesday. Key Points
ReutersSupreme Court weighs landmark Purdue Pharma settlement impacting opioid crisis
The Supreme Court weighs a pivotal Purdue Pharma settlement shielding the Sackler family from opioid crisis lawsuits. The $6 billion agreement, aimed at combatting the epidemic, faces scrutiny over extending bankruptcy protection to non-bankrupt individuals. Supporters view it as crucial, while critics decry special treatment for the Sacklers. The verdict, expected by summer, could reshape opioid litigation, offering direct payouts to victims and addressing the impact of OxyContin's marketing on the crisis. Key Points
Economic TimesPharma cos' likely re-rating, strong outlook to sustain rally
In the past month, Sun Pharma gained 7%, Aurobindo Pharma jumped 20%, Lupin and Mankind Pharma rose 9% each. The gains have pushed these stocks to their 52-week highs. The Nifty Pharma Index has gained 8% in the past month, as against the 3.4% upmove in the Nifty. Key Points
Economic Times
Gland Pharma share price rise 6% after USFDA completes inspection of Hyderabad facility
Gland Pharma share price witnessed a 6.5% surge on Friday following the company's announcement that the United States Food and Drug Administration (USFDA) had successfully concluded its inspection of the Pashamylaram facility in Hyderabad. Key Points
mintParam Desai’s 4 top picks in largecap and midcap pharma
“We believe that Ciplas Pithampur facility was inspected in February and post that, they got an OAI in August and post that, it has escalated to a warning letter. We believe that it is unlikely that this will escalate further to import alerts, though this may take some time to resolve.” Key Points
Economic TimesNew tailwinds emerge! 5 midcap Pharma stocks with upside potential of up to 37%
If one looks at corporate announcements, a large number of small and mid-caps Pharma companies are announcing one or the other thing either about US FDA or European authorities giving approval or inspection. While the large players had moved to international markets a long time back, a number of small companies that had domestic focussed business are also moving into the developed global markets. Will this lead to re-rating? Key Points
Economic TimesEarnings season held up well; positive on Cipla and Sun Pharma: Mayuresh Joshi
The BFSI space has held up well. Midcap IT has produced another quarter of stupendous earnings and management commentaries are pointing out towards no damage to probably come from either the pricing action or demand dynamics at least at this juncture. A few of the capital good companies obviously have reported a strong set of numbers and though cement companies have disappointed, the reason is obvious. Q2 is expected to be weak for monsoons. Key Points
Economic TimesIsrael-Hamas war may singe billion-dollar Pharma exports
“Indias exports amount to a billion dollars per year in these countries,” one of the experts said, asking not to be named. He said a protracted Israeli-Palestinian war would impact flight services to these countries and subsequently hit Pharma exports from India. Key Points
Economic Times
3 Pharma stocks to buy on dips; 3 banks that may outperform: Sanjiv Bhasin
“ HDFC Bank is a very good long-term and a slightly medium-term play. I do not rule out Bank Nifty going back to test 46,000 in this month itself and I would be very bullish on select banks like AU Bank, IDFC and RBL Bank which are three banks where we are taking exposure and we think can outperform.” Key Points
Economic TimesA Healthy Dose! 4 midcap Pharma stocks with upside potential of up to 36%
After a long period of under performance, Pharma stocks have seen interest coming back from institutional investors. This is because some tailwinds have emerged recently, shortage in some segments in the generic market in the US have led to sharp spikes in prices in some of the generic medicines. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic Times4+1 stocks that Dipan Mehta would keep in his 5-year-plus basket
Whenever we have seen a change of management like this, it has worked positively for shareholders. Look at what happened in JB Chemicals, and even then UniChem. All the acquisitions which have taken place in the Pharma industry have been very positive for both the acquirer as well as the acquired company. They also have been able to unlock a lot of synergy. So I am very positive on this particular development in Cipla, being a shareholder and a disclosure, we and our clients are invested in it. Key Points
Economic TimesTorrent joins fray for Hamied family stake in Cipla, up against Blackstone and Baring PE
Torrent Pharma is reportedly vying to acquire the Hamied family's stake in Cipla, which could become the largest pharmaceutical deal since 2014. If successful, the deal could create India's second-largest drugmaker by revenue. Other potential buyers include Blackstone and Baring PE Asia-EQT. Torrent Pharma is said to be forming a consortium with private equity funds and has approached multiple lenders for funding. Key Points
Economic TimesFinally out of the woods? 5 small and midcap Pharma stocks with an upside potential of up to 23%
Pharma as a sector, both in terms of business and stocks price performance has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, recently some tailwinds have emerged both for the companies focussing on domestic Pharma and also the ones focussed on the US generic market. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic Times
At the right time, money can be made in pharma; hold on to HDFC Bank: Mayuresh Joshi
NIM contraction might be very marginal in HDFC Bank. Advances growth should be extremely strong. Again, purely in terms of their advances and deposit growth, the numbers are pretty humongous . All the tech issues are largely behind them. Even if valuations are at a premium, which it has always commanded, the second half numbers should be relatively better. Key Points
Economic TimesAuto, Pharma stocks offering margin of safety top funds' buy list in July
Shares in the Pharma and automotive sectors were among those that fit the bill. Fund managers lapped up Pharma given the recent underperformance, lower input prices and attractive valuations. With first-quarter results encouraging, they bought into stocks like Dr Reddy's Laboratories, Aurobindo Pharma, and Suven Pharmaceuticals. Key Points
Economic TimesFinally out of the woods? 4 midcap Pharma stocks with an upside potential up to 34 %
Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However some tailwinds have emerged recently, shortage in some segments in the generic market in the US have led to sharp spikes in prices. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesManforce condoms maker Mankind Pharma posts 66% jump Q1 profit
India's Mankind Pharma Ltd (MNKI.NS) posted a 66% jump in June-quarter profit on Wednesday, its second quarterly results since listing in May this year, helped by strong domestic sales and continued growth in the company's chronic drugs segment. Key Points
ReutersAurobindo Pharma jumps 91%, others gain up to 94% this year: Why are Pharma stocks rising - Explained
Pharma stocks in India have been outperforming the benchmark index Nifty50 this year. Factors driving the gains include improved performance in the US generics market, robust performance in branded markets, lower raw material costs, and market share gains in new products. Key Points
mint
Nischal Maheshwari on 6 stock picks in Pharma and IT
“We continue to like largecap Pharma stocks. Aurobindo Pharma has done well, coming up from the bottom and they are getting their act right. That is a bit of an outlier but looks interesting at these prices. So our top picks out there are Sun Pharma and Dr Reddys, followed by Aurobindo.” Key Points
Economic TimesWhat to buy in Pharma stocks? Rahul Shah answers
“Pre-Covid most of the Pharma stocks rallied and the same was the case with Biocon and then it has done nothing in the last two years. So if I have to look at in terms of market cap, the stocks look cheap but in terms of valuation, it looks fully valued at current levels as well. I do not see any major upside happening in Biocon.” Key Points
Economic TimesFinally out of the woods? 4 small and midcap Pharma stocks with an upside potential of up to 26%
Pharma as a sector has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, some of the small and mid sized Indian Pharma companies which are not hit by pricing pressure of the US generic market and other issues which large Pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesOn path to recovery: 4 small- and mid-cap Pharma stocks with upside potential up to 27%
Pharma as a sector has been under pressure for a very long time. However, some of the small and mid sized Indian Pharma companies which are not hit by pricing pressure of the US generic market and other issues which large Pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesPiramal Pharma may double in a year; 4 metal stocks can give 20% return in 3 months : Sanjiv Bhasin
Jindal Steel has become an extremely attractive buy at this price, along with Tata Steel. Other than steel, Hindalco and Hindustan Copper. If you have a three-month period, these stocks can give a 20% return as both ferrous and non-ferrous have come back on the table with China spending and the underperformance coming to an end. Key Points
Economic Times
JB Pharma scouts for acquisitions, eyes bigger pie of domestic market
Having invested about $200 million in four acquisitions in the last 15 months, JB Chemicals & Pharmaceuticals Ltd. (JB Pharma), majority owned by private equity firm KKR, is scouting for more acquisitions to broad base its offerings as well as to grow its ranking in the Indian pharmaceutical sector. Key Points
The HinduOn a path to recovery: 4 small Pharma stocks with an upside potential of up to 27%
As the markets get jittery, select Pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian Pharma companies which are not hit by pricing pressure of the US generic market and other issues which large Pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesI-T dept searches Mankind Pharma’s office days after successful listing, shares tank
While Mankind Pharma shares recovered after the initial blow, they were trading 2.38 per cent lower at Rs 1,350 apiece at 11:00 am. While the stock fell today, it still remains well above its IPO price of Rs 1,080. Key Points
India TodayNifty healthcare index stocks analysts suggest buying have potential upside of more than 19%
Except for a pocket in which demand for covid drugs led to sharp surge in Pharma stocks, the Pharma sector had been under pressure for a long time. After a long phase of consolidation, in which some companies have implemented change in their business model, are Pharma stocks close to breakout ? Stock Reports Plus, powered by Refinitiv, is a comprehensive research report that evaluates five key components of 4,000+ listed stocks - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores. Key Points
Economic TimesMankind Pharma shares tank over 6% a day after solid debut. Time to buy?
Shares of Mankind Pharma fell more than 6%, a day after its listing on the Indian stock exchanges at a premium. The company's IPO was the largest so far this year and one of the biggest ever by a domestic drug maker since Gland Pharma's offering in 2020. Mankind Pharma is India's fourth-largest pharmaceutical company in terms of domestic sales and operates 25 manufacturing facilities across the country. Antique and Macquarie have initiated coverage on Mankind Pharma with buy and outperform ratings, respectively and optimistic about the firm's future growth. Key Points
Economic Times
31% listing pop! Time to book profits in Mankind Pharma shares?
Its shares are currently trading nearly 6.7% higher at Rs 1,387. The IPO received a strong response, with the issue subscribed for 15.32 times, primarily driven by QIBs. However, retail investors did not show much interest. Following the listing, Macquarie initiated coverage on Mankind Pharma with an 'outperform' rating and target price of Rs 1,400 based on the company's net profit potential, shift towards chronic therapies and unlocking of operating leverage. Key Points
Economic TimesBumper market debut for Mankind Pharma, shares surge nearly 30%
Shares of Mankind Pharma were trading at Rs 1,390.55 apiece, up 28.75 per cent at 11:05 am on the National Stock Exchange. The market capitalisation of the company also jumped to Rs 55,830 crore. Key Points
India TodayMankind Pharma set for stellar debut on Monday, Street sees 8-10% listing premium
Mankind Pharma's shares are commanding a premium of Rs 100-113 to its issue price of Rs 1,080 in the grey market. Research analysts predict an 8-10% higher opening on the listing day. At Rs 1,080 a share, Mankind Pharma is valued at a price-to-earnings of 30 times its FY22 earnings, valuing the company at Rs 44,000 crore post-IPO. Although Mankind Pharma is the fourth-largest Indian pharmaceutical company in terms of domestic sales, investors are advised to book profits on listing day given the expensive valuations of the stock versus peers. Key Points
Economic TimesAjanta Pharma Q4 earnings: Net profit down 19% in Q4, R&D expenses up 7%
Ajanta Pharma, a mid-size firm, closed today's trading session with a market worth of ₹16,201.44 Cr. Key Points
mintPI Industries' foray into Pharma to help it replicate agrochem success: Rohan Gupta
PI Industries' foray into the Pharma industry through two acquisitions will diversify its business and reduce its dependency on agro. The access to CDMO business of Pharma will give the company access to global markets in the US, India, and Italy. The deal, valued at 4.2x EV/EBITDA, will be EPS accretive on existing numbers alone and is expected to be 7-8% EPS accretive going forward, with further growth of the two acquired companies contributing to 12-15% EPS growth over the next two years. Key Points
Economic Times
Mankind Pharma IPO subscribed 15.32 times
This will be one of the largest public issues by a domestic drug manufacturer after the ₹6,480-crore IPO of Gland Pharma in 2020. The qualified institutional buyers (QIB) category was subscribed 49 times, while the non-institutional investors or high net-worth individuals' portion was subscribed 3.8 times. However, the retail investor's portion was under-subscribed at 92%. Key Points
Economic TimesMankind Pharma IPO sails through on Day 3
The IPO was subscribed 2.08 times so far on Day 3, with non-institutional investors (NIIs) and qualified institutional buyers (QIB) doing the heavy lifting. The NII part was subscribed 1.34 times while the QIB category was subscribed 5.68 times. Key Points
Economic TimesMankind Pharma IPO subscribed 32% so far on Day 2. Check GMP and other details
Mankind Pharma's initial public offering (IPO), which will close on January 19, has been subscribed by 32% on Day 2 with non-institutional investors and qualified institutional buyers subscribing the most. Retail investors' quota had 16% bids. Nine brokerages recommended the issue, saying that growth opportunities outweigh concerns about high valuation. Mankind Pharma has raised around Rs 1,297 crore by allocating 1.2 crore equity shares to 77 anchor investors, which include Goldman Sachs, Canada Pension Plan and Government of Singapore. At the higher end of the price band, Mankind Pharma valued at 30x FY22 EPS. Key Points
Economic TimesOn a path to recovery: 5 midcap Pharma stocks with an upside potential up to 32%
As the markets get jittery, select Pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are mid-sized Indian Pharma companies which are not hit by pricing pressure of the US generic market and other issues which large Pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesBe careful about overtly optimistic IT cos; it will be tough for Reliance to disappoint: Sandip Sabharwal
Sandip Sabharwal is optimistic about the growth prospects of large banks in India, particularly ICICI Bank. He also highlights the railway investment theme as strong and suggests identifying stocks that can benefit disproportionately. In terms of IT, while there is a definite slowdown that could persist over the following year, there are specific companies with specific projects or businesses that will stand out. Key Points
Economic Times
What are the sectors to position in for the next market upcycle? Abhishek Basumallick answers
Banking, NBFCs, and MFIs are good places to invest as the Indian banking sector has cleaned up its books, making credit growth pick up significantly. Capital goods and power sector are well-poised for growth in the next 2-3 years with high government investment in railways, highways, and airports. Companies in the capital goods sector, despite some trading at high price-to-earnings ratios, are expected to contract PEs due to anticipated high growth in the next few quarters. Additionally, the Pharma sector is expected to show strong earnings growth in the next 2-3 years. Key Points
Economic Times2023 will be a volatile year; use stock rotation and buy on dips: Sandeep Tandon
Stock rotation is the theme to play within a volatile market, according to Sandeep Tandon, Founder of Quant Broking. He believes that the buy on dips strategy should work now and that any events unfolding because of the global situation should be used as a buying opportunity. Tandon also explained that Quant Broking has experienced AUM growth due to the trust of lakhs of investors and distributors in their processes, risk management system, and investment framework Key Points
Economic TimesOn a path to recovery; 5 mid-cap Pharma stocks with an upside potential up to 41%
As the markets get jittery, select Pharma stocks are back in focus. This tends to happen in bearish markets. Some of them are mid-sized Indian Pharma companies which are not hit by pricing pressure of the US generic market and other issues which large Pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list. Key Points
Economic TimesPharma on a very good wicket; double digit growth likely next year: Kewal Handa
The pharmaceutical sector in India is showing strong domestic growth of 7% to 9%, despite flat global growth in the US and Europe, according to Pharma expert Kewal Handa. He sees good opportunities for Indian companies in the US, as a significant number of patents are set to expire in the next five years. Biosimilars and the application of artificial intelligence in R&D are expected to be major growth areas, and Handa predicts double-digit growth next year. Key Points
Economic TimesSaroja Pharma Industries IPO: GMP, subscription status on day 1, other key details
Saroja Pharma Industries IPO opens with a price band of ₹84 per share, plans to raise funds for expansion and debt repayment. IPO subscription at 79% on day 1. Key Points
mint
We are looking to add Pharma stocks to our portfolio, find multiplex stocks too expensive: Deepak Shenoy
There will be a lot more demand for both railways and defence orders that are coming in and while these stocks have run up quite a bit, there is actually a significant room for growth from here even though the prices have run up. Also, some of the domestic consumption stories and high precision engineering stories will make a difference. Key Points
Economic TimesOMCs a short-term play; beware of froth in IPO market: Nitin Raheja
Nitin Raheja says: “There is a lot of visible froth that we see in the IPO markets presently. But there is just so much domestic liquidity today and that is prevailing and chasing. Also, if you see promoters selling, the way PE and VCs have been selling, point to froth in the market and one has to be careful.” Key Points
Economic TimesTime to lock profits in RailTel, IRFC and IRCTC as charts looking overbought: Aditya Arora
Aditya Arora of Adlytick believes that stocks like RailTel, RVNL, Tourism Finance, PVR-Inox, Mphasis, Torrent Pharma, SIS, and Praveg are overvalued and overbought. In the technology sector, he recommends buying Mphasis with a target of 2700. He also recommends Torrent Pharma as a Pharma pick with a target of 2600-2700. SIS is another stock he finds attractive with a target of 580 to 600. Key Points
Economic TimesAurobindo Pharma share price rises more than 1% on regulatory clearance of manufacturing facilities
Stock Market today- Share price of Aurobindo Pharma gained as regulatory clearance of plants lifted sentiments. The US sales contribute more than half to Aurobindo's sales and compliance of manufacturing units to the norms laid by the US drug regulator on good manufacturing practices is important. Key Points
mintSekhmet, Nirma in fray for Glenmark's API business
Sekhmet Pharmaventures and Nirma Group are in competition to acquire Glenmark Life Sciences (GLS), the 82.85% subsidiary of Glenmark Pharmaceuticals. The firm will reportedly sell the API developer and manufacturer in bid to deleverage. Many sources, including ChrysCapital, are said to be looking at the opportunity, but have yet to make any binding bids. Since Glenmark's share price peaked at Rs 595 last week, the company has grown in value to have a market cap of Rs 7,232 crore. Rising dependence on imports of APIs and bulk drugs has made it an area of interest for India's government, which is seeking to incentivise domestic production. Key Points
Economic Times
Mankind Pharma IPO opens for subscription today: Should you bid?
The issue opens for subscription today and will be available for the public to bid till April 27. Investors can bid for 13 shares in one lot and in multiples thereof. The price band is set at Rs 1,026-1,080 per share. Key Points
Economic TimesVikas Khemani explains why big money can be made in pharma
Vikas Khemani of Carnelian Capital Advisors discusses the growth potential of the Pharma sector and the positive outlook for IT companies like TCS and Infosys. He believes that the underperformance of Pharma over the past seven to eight years is coming to an end, with a promising trend emerging in both the US and domestic markets. Khemani also highlights the long-term investment opportunities in the IT sector, particularly with the decline in US interest rates. Key Points
Economic TimesSun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 million
Lyndra Therapeutics Inc. is in the business of developing novel delivery technology for long-acting oral (LAO) therapies. Key Points
Business TodayMayuresh Joshi on 3 stocks that can be bought on dips now
Mayuresh Joshi, Head-Equity Research India at William O'Neil, recommends buying opportunities in stocks like Exide, Amara Raja, and Pidilite in the midcap space. He also suggests considering midcap IT stocks and Pharma companies like Sun Pharma, Cipla, Natco, and Torrent Pharma. Joshi says they will be keeping eyes open for any pullback in stocks like Persistent and Coforge within midcap IT space. Key Points
Economic TimesKKR considers selling stake in India’s $3 billion JB Pharma
KKR & Co. is reportedly considering selling its 53.8% controlling stake in Indian pharmaceutical company JB Chemicals & Pharmaceuticals Ltd. The US private equity firm is said to be exploring options and seeking financial advisers for a potential sale, with other buyout firms and industry players expressing preliminary interest. JB Pharma's shares have seen a 68% increase in the past year, valuing the company at just over $3 billion. Key Points
Economic Times
‘Pharma exports expected to touch $28 billion in FY24’
Indian Pharma exports may touch $28 billion during the current fiscal against $25.39 billion in FY23, Udaya Bhaskar, Director General of Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body under the Department of Commerce said on Tuesday. Key Points
The HinduUS-based Advent seeking investors for Suven-Cohance merger
Advent announced its acquisition of Suven Pharma in December. Including the cost of the open offer, the deal size would go up to Rs 9,589 crore. The deal was given a green light by the union cabinet on September 14. A Suven Pharma-Cohance combination could bring together the strong client base of the former, which is a drug development partner to large global pharmaceutical companies. Key Points
Economic TimesTorrent Pharma says it has no disclosure to make now on potential Cipla stake buy deal reports
Torrent Pharma has stated that it does not have any information to disclose under listing regulations, in response to reports about the company's talks to acquire a stake in Cipla. While the company did not deny the developments, it mentioned that it does not comment on speculative reports without verified data. Torrent Pharma is reportedly making efforts to secure financing for the acquisition. Key Points
Economic TimesSiddhartha Khemka on why Bajaj Finance saw a sell-off post results
Mumbai-based MOFSL's Siddhartha Khemka says he has a positive view on Bajaj Finance despite the recent sell-off in response to its in-line Q1 results. He said the addition of new products to its range of services should help the firm grow. Khemka also expects broad-based improvement in India's healthcare market, adding that the regulatory uncertainty which has hung over the sector has eased somewhat, with some Pharma firms already reporting better numbers. Khemka says he prefers Sun Pharma rather than Cipla or other local Pharma names. Key Points
Economic TimesMankind counters objections raised by chemists body on supplement ad
Mankind Pharma, ranked as the fourth largest pharmaceutical company in the country, has responded to objections raised by a retail chemists' association regarding its advertisement for the vitamin supplement, HealthOK. The All India Organisation of Chemists and Druggists (AIOCD) had requested the withdrawal of the advertisement, alleging that it implies non-vegetarians are healthier due to its portrayal of actor Ranveer Singh. In a letter dated February 13th, Mankind Pharma addressed the concerns raised by the AIOCD. Key Points
Economic Times
Defensive bet with macro tailwinds? 5 Indian Pharma stocks with upside potential of up to 20%
On Tuesday, when the whole market was reeling under pressure, two stocks reacted to their numbers in a positive direction. Both of them were large caps from one sector which is pharma. This becomes significant from three perspectives. First, that positive reaction was there on the day when there was a bloodbath on the street. Second, these stocks were already sitting on gains, so there is little probability of short covering leading to this sort of gains. Last but not the least it has come from sectors like Pharma which have seen a very long phase of business remodelling and valuation readjustment, which makes it worth noticing. It might be too early to call, but if a re-rating gets momentum then they might be candidates for volatile markets. Key Points
Economic TimesMedicine for bearish markets: 5 Indian Pharma stocks with upside potential of up to 32%
There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising interest rates and other economic headwinds have little impact on their working because they are taking care of a need which is very basic in nature and if spending has to be done on that, it cannot be postponed. Pharmaceutical companies come into that category. This is not to say that there was a phase of almost 7 years that Pharma stocks became under-performers. That was a very different reason, most of which have been taken care of. So there is a good chance that this time Pharma stock will be able to tackle bears in a much better way. Key Points
Economic TimesSun facing some clouds is still a buy for analysts
Shares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% from the previous close. More than 5.6 million shares exchanged hands on the BSE and NSE on Monday, over twice its combined average daily volume for the last month. Key Points
Economic TimesMankind Pharma IPO Day 1: Issue subscribed 14%, HNIs subscribed one-third of quota
Qualified institutional buyers (QIBs) subscribed for 8% of their reserved portion. Retail investors bid 14,39,737 times of the shares reserved for RIIs. Key Points
FinancialexpressPharma offsetting some of the impact from IT: Vinod Karki
The soft outlook on IT is being compensated by Pharma exports, says Vinod Karki, ICICI Securities' equity strategist. He adds that while the Indian IT services sector doesn't have any structural issues, resetting itself is painful, with short-term uncertainty. However, the investment cycle aided by real estate and manufacturing cycles give confidence that future demand will be sustained, meaning the earnings downgrade cycle will not be there. Key Points
Economic Times
Amnish Aggarwal on 7 Pharma and insurance stocks to bet on
“Insurance is one of the most interesting segments in the long term. Over the last two to three years, insurance stocks have underperformed – be it life insurance or general insurance companies. In the long term, both life as well as general insurance companies have a lot of scope for consistent and steady returns. ” Key Points
Economic TimesTime to tilt towards largecaps; 3 sectors to get into on correction: Nitin Raheja
Nitin Raheja advises largecaps amid corrections in mid and smallcaps. Financials face challenges, chemical companies show resilience. Birla Group unlocking value. Caution on FMCG and battery stocks. Pharma presents defensive play with growth potential. Key Points
Economic TimesSectoral tailwinds and stronger balance sheets: 5 largecap stocks with right mix of two important ratios
There are some sectors where large players have an edge, because the nature of the business is such that there are phases where ability to stay in the game and cash on the balance sheet matter most. When the tide turns in favor of that sector, these large companies are able to make most of it. One sector which has gone through a phase of realignment of business and readjustment of valuations for many years and has once again come in limelight is the Pharma space. Right from ability to deal with USFDA, not rely just on product segment to how to deal with uncertainty of supply chain which is dependent on China, Indian Pharma companies have come a long way. Key Points
Economic TimesSun Pharma to acquire remaining stake in subsidiary Taro for $348 million
India Business News: Sun Pharma announces the acquisition of the remaining stake in its subsidiary Taro for $348 million. Find out more about this strategic move and its impact on the pharmaceutical industry. Key Points
Times Of IndiaGetting back into shape? 6 Indian Pharma stocks with upside potential of up to 41%
The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were Pharma stocks. While it might appear to be a sudden up move, if one looks at what has happened in the Pharma sector in the last eight years, there is a good chance that right from valuation readjustments to changing business model might play a role bringing the large Pharma companies back into limelight. Infact some of these stocks have quietly inched upward in the last few months. It might be too early to call, but if a re-rating plays out in this space, it might surprise many in terms of price movement. Key Points
Economic Times
Looking for anti-consensus ideas? Jyotivardhan Jaipuria says only 2 sectors left
“Pharma had been going through bad times for the last 18 months in terms of stock price. Earnings were not that great but will turn around and that is one segment where we are playing. IT is also there. It is coming on our horizon after a long time. Because we have been underweight on this for quite some time, like we used to say, buy local, avoid global.” Key Points
Economic TimesWhat India's top mutual fund houses bought, sold & completely exited in October
The Nifty Pharma index is trading at a price-to-earnings multiple of 31, lower than its five-year average of 36. Fund managers bought into stocks like Aurobindo Pharma, Cipla, Pfizer, Lupin, JB Chemicals, Alkem, and Syngene International. Key Points
Economic TimesNifty healthcare index stocks; Staying bullish on select Pharma and hospitals
While they clubbed together, the operating matrix of a Pharma company making drugs and hospital and a diagnostic company are very different. We take a look at what analysts are saying about different stocks from each of these segments. Stock Reports Plus, powered by Refinitiv, is a comprehensive research report that evaluates five key components of 4,000+ listed stocks - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores. Key Points
Economic TimesIndia's Gland Pharma posts 41% jump in quarterly revenue on Cenexi acquisition
Indian generic injectables maker Gland Pharma Ltd (GLAD.NS) reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi. Key Points
ReutersMankind Pharma director sells South Delhi bungalow for ₹91 crore
In Vasant Vihar, plot sizes range from 450 square meters to 2,000 square meters, and many of them have become available for sale after the lifting of the lockdown, said an industry expert. Numerous individuals are now seeking to liquidate their assets. The advantage of larger plots in South Delhi is that buyers can redevelop the land and construct up to four floors, a privilege not permitted in Lutyens' Delhi. Key Points
Economic Times